Brandon Blue

512 total citations
27 papers, 163 citations indexed

About

Brandon Blue is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Brandon Blue has authored 27 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 12 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Brandon Blue's work include Multiple Myeloma Research and Treatments (15 papers), CAR-T cell therapy research (6 papers) and Protein Degradation and Inhibitors (6 papers). Brandon Blue is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), CAR-T cell therapy research (6 papers) and Protein Degradation and Inhibitors (6 papers). Brandon Blue collaborates with scholars based in United States, Puerto Rico and Greece. Brandon Blue's co-authors include Kristen M. Sanfilippo, Suhong Luo, Kenneth R. Carson, Katiuscia O’Brian, Jesse Keller, Brian F. Gage, Tzu‐Fei Wang, Kenneth H. Shain, Taiga Nishihori and Melissa Alsina and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Brandon Blue

22 papers receiving 162 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brandon Blue United States 6 79 72 68 46 22 27 163
Christiane Walter Germany 8 126 1.6× 105 1.5× 25 0.4× 45 1.0× 23 1.0× 18 191
Mohan K. Tummala United States 9 50 0.6× 88 1.2× 50 0.7× 27 0.6× 10 0.5× 17 176
Αριστέα-Μαρία Παπανώτα Greece 11 96 1.2× 95 1.3× 57 0.8× 61 1.3× 18 0.8× 27 206
Sue Naim United States 5 134 1.7× 233 3.2× 43 0.6× 37 0.8× 27 1.2× 8 299
Johanna Mondésir France 4 34 0.4× 96 1.3× 41 0.6× 69 1.5× 58 2.6× 8 193
Fatima Zahra Jelloul United States 8 92 1.2× 61 0.8× 63 0.9× 16 0.3× 34 1.5× 32 172
Christine Moung United States 6 48 0.6× 38 0.5× 41 0.6× 43 0.9× 27 1.2× 10 153
Kaiyang Ding China 9 107 1.4× 100 1.4× 113 1.7× 28 0.6× 30 1.4× 51 241
Renata Bezděková Czechia 5 85 1.1× 90 1.3× 37 0.5× 61 1.3× 27 1.2× 16 148
Sumito Shingaki Japan 4 23 0.3× 87 1.2× 35 0.5× 33 0.7× 16 0.7× 15 134

Countries citing papers authored by Brandon Blue

Since Specialization
Citations

This map shows the geographic impact of Brandon Blue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brandon Blue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brandon Blue more than expected).

Fields of papers citing papers by Brandon Blue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brandon Blue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brandon Blue. The network helps show where Brandon Blue may publish in the future.

Co-authorship network of co-authors of Brandon Blue

This figure shows the co-authorship network connecting the top 25 collaborators of Brandon Blue. A scholar is included among the top collaborators of Brandon Blue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brandon Blue. Brandon Blue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Whiting, Junmin, Jongphil Kim, Doris K. Hansen, et al.. (2025). Incidence and clinical predictors of cranial nerve palsies (CNPs) post ciltacabtagene-autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations
2.
Menges, Meghan, Elliot Merritt, Omar Castañeda Puglianini, et al.. (2025). Advancing Soluble BCMA Quantification in Immunotherapy: Analytical Validation of ELLA Versus ELISA for Predicting Toxicity and Response. Clinical Lymphoma Myeloma & Leukemia. 25. S143–S143.
3.
Meads, Mark B., Xiaohong Zhao, David Noyes, et al.. (2024). De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression. Blood. 144(Supplement 1). 1906–1906.
4.
Grajales‐Cruz, Ariel, Doris K. Hansen, Brandon Blue, et al.. (2024). P-027 Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S56–S56. 1 indexed citations
5.
Puglianini, Omar Castañeda, Doris K. Hansen, Brandon Blue, et al.. (2024). Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.. Journal of Clinical Oncology. 42(16_suppl). 7524–7524. 1 indexed citations
6.
Ionescu, Filip, Pragi Patel, Praneeth Sudalagunta, et al.. (2024). Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM). Blood. 144(Supplement 1). 4740–4740.
7.
Blue, Brandon, et al.. (2023). Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23(9). 651–659. 3 indexed citations
8.
Akhtar, Othman Salim, Doris K. Hansen, Melissa Alsina, et al.. (2023). Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology. 15(2). 101628–101628. 15 indexed citations
9.
Bhutani, Manisha, Brandon Blue, Craig E. Cole, et al.. (2023). Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer Journal. 13(1). 189–189. 17 indexed citations
10.
Grajales‐Cruz, Ariel, Brandon Blue, Doris K. Hansen, et al.. (2023). P-012 Safety and efficacy of standard of care (SOC) teclistamab (TEC) in patients with relapsed/ refractory multiple myeloma (RRMM), a single center experience. Clinical Lymphoma Myeloma & Leukemia. 23. S39–S40. 1 indexed citations
11.
12.
Hansen, Doris K., Lauren C. Peres, Kayla Reid, et al.. (2023). A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel. Blood. 142(Supplement 1). 1004–1004. 2 indexed citations
13.
Zhang, Yumeng, Jason Brayer, Frederic J. Reu, et al.. (2022). Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clinical Lymphoma Myeloma & Leukemia. 22(8). e770–e776. 2 indexed citations
14.
15.
Blue, Brandon, Doris K. Hansen, Yumeng Zhang, et al.. (2020). Impact of doxycycline on outcomes in AL amyloidosis.. Journal of Clinical Oncology. 38(15_suppl). e20568–e20568. 1 indexed citations
16.
Shain, Kenneth H., Daniel P. Hart, Praneeth Sudalagunta, et al.. (2019). Reinforcement Learning to Optimize the Treatment of Multiple Myeloma. Blood. 134(Supplement_1). 5511–5511. 3 indexed citations
17.
Blue, Brandon, et al.. (2018). Outcomes of Autologous Stem Cell Transplant in Lymphoma Patients with Mild Renal Impairment. Biology of Blood and Marrow Transplantation. 24(3). S258–S259.
18.
Sanfilippo, Kristen M., Jesse Keller, Brian F. Gage, et al.. (2016). Statins Are Associated With Reduced Mortality in Multiple Myeloma. Journal of Clinical Oncology. 34(33). 4008–4014. 68 indexed citations
19.
Blue, Brandon, et al.. (2016). Race‐based differences in routine cytogenetic profiles of patients with multiple myeloma. British Journal of Haematology. 176(2). 322–324. 6 indexed citations
20.
Cheema, Asima, Ana Paula Velez, Maria M. Medveczky, et al.. (2012). Encephalitis and Inherited HHV-6. Infectious Diseases in Clinical Practice. 20(6). 419–421. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christiane Walter Breakdown of academic impact, for papers by Mohan K. Tummala Breakdown of academic impact, for papers by Αριστέα-Μαρία Παπανώτα Breakdown of academic impact, for papers by Sue Naim Breakdown of academic impact, for papers by Johanna Mondésir Breakdown of academic impact, for papers by Fatima Zahra Jelloul Breakdown of academic impact, for papers by Christine Moung Breakdown of academic impact, for papers by Kaiyang Ding Breakdown of academic impact, for papers by Renata Bezděková Breakdown of academic impact, for papers by Sumito Shingaki
Rankless by CCL
2026